ARS Pharmaceuticals, Inc.
SPRY
$5.24
-$0.16-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 114.15% | 184.47% | -67.56% | 1,471.62% | 3,043.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.15% | 184.47% | -67.56% | 1,471.62% | 3,043.40% |
| Cost of Revenue | 94.52% | 162.53% | 146.58% | 141.28% | 30.79% |
| Gross Profit | 140.58% | 207.08% | -77.64% | 973.90% | 204.72% |
| SG&A Expenses | 42.84% | 75.66% | 68.93% | 287.69% | 507.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.20% | 83.45% | 76.60% | 259.81% | 299.82% |
| Operating Income | -29.09% | -61.78% | -187.86% | -144.58% | -210.39% |
| Income Before Tax | -38.89% | -78.60% | -182.44% | -167.41% | -258.60% |
| Income Tax Expenses | -- | -- | -127.78% | -- | -- |
| Earnings from Continuing Operations | -38.89% | -78.60% | -182.76% | -167.41% | -258.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.89% | -78.60% | -182.76% | -167.41% | -258.60% |
| EBIT | -29.09% | -61.78% | -187.86% | -144.58% | -210.39% |
| EBITDA | -28.97% | -61.93% | -186.92% | -143.02% | -208.93% |
| EPS Basic | -37.56% | -76.39% | -181.39% | -162.66% | -252.90% |
| Normalized Basic EPS | -37.55% | -76.38% | -164.86% | -162.66% | -252.97% |
| EPS Diluted | -37.56% | -76.39% | -199.74% | -162.66% | -252.90% |
| Normalized Diluted EPS | -37.55% | -76.38% | -179.40% | -162.66% | -252.97% |
| Average Basic Shares Outstanding | 0.97% | 1.26% | 1.67% | 1.83% | 1.58% |
| Average Diluted Shares Outstanding | 0.97% | 1.26% | -16.93% | 1.83% | 1.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |